Fierce Biotech1 min read
saveCG preps new, expanded bladder cancer plans with FDA after ph. 3 win
CG Oncology showed in a late-stage study that its immunotherapy cretostimogene reduced the risk of tumor recurrence in certain patients with non-muscle invasive bladder cancer following surgery.
comments(0)
5-min edit window · permanent after that